Fondaparinux is a selective factor Xa inhibitor. Benefits of fodaparinux vs. heparin when anticoagulants are used in ACS:
1. It is not associated with heparin induced thrombocytopenia.
2. Significant reduction in 30-day and 6-month mortality vs. enoxaparin.
3. Significant reduction in bleeding complications.
4. Safer in patients with renal insufficiency vs. enoxaparin.
Unfractionated heparin should be continued while the patient goes for PCI.